KORU Medical Systems (KRMD)

• Market cap: $184M
• 1 day: 8.65%
• 5 days: -7.59%
• 1 month: 10.14%
• 3 months: 49.44%
• 6 months: 71.06%
• Year to date: 68.91%
• 1 year: 74.03%
• 5 years: -38.53%
• 10 years: 1.26%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Employees: 82

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more call options, than puts

Call options by funds: $20K | Put options by funds: $10K

3.86% less ownership

Funds ownership: 31.71% [Q2] → 27.85% (-3.86%) [Q3]

9% less capital invested

Capital invested by funds: $38.5M [Q2] → $34.9M (-$3.58M) [Q3]

17% less funds holding

Funds holding: 65 [Q2] → 54 (-11) [Q3]

54% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 24

69% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 16

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3.50 13% downside
• Avg. target: $4.17 4% upside
• High target: $5 24% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Craig-Hallum Chase Knickerbocker 43% 1-year accuracy 10 / 23 met price target	24% upside $5	Buy Maintained	14 Nov 2024
Canaccord Genuity Caitlin Cronin 58% 1-year accuracy 7 / 12 met price target	1% downside $4	Buy Maintained	14 Nov 2024
Piper Sandler Jason Bednar 50% 1-year accuracy 19 / 38 met price target	13% downside $3.50	Overweight Maintained	14 Nov 2024